“The association between CKD and end-stage renal failure and increasing risk of kidney cancer is a really striking and important association to be aware of,” says Sarah P. Psutka, MD, MS.
In this video, Laura Bukavina, MD, MPH, and Sarah P. Psutka, MD, MS, discuss the background and recent findings from the European Urology study, “Epidemiology of Renal Cell Carcinoma: 2022 Update.” Bukavina is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Psutka is an associate professor of urology at University of Washington Medical Center, Seattle.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.